GSK's Accelerate Growth: A Pipeline-Fueled Reshaping

A Disciplined Reallocation

GSK's July 28 report was less about the quarter—sales up 5% to £8.4bn, core EPS up 9%—and more about the future shape of the company. The headline was the Accelerate Growth program, a £1.9bn annual savings initiative by 2029, funded by a £2.4bn upfront charge. As CEO Luke Miels put it: “we have announced today an accelerate growth program. This program is about reallocation within our existing P&L to fund these studies and labs.” — Luke Miels, CEO · 2026-07-28 The savings are being steered toward a late-stage pipeline that has essentially doubled its blockbuster potential since 2022. Tony Wood, head of R&D, added: “We've more than doubled the number of Phase II and Phase III assets with blockbuster potential since 2022.” — Tony Wood, Head of R&D · 2026-07-28 This is not a defensive move; it's a deliberate shift toward specialty and oncology, with 6 of the 7 accelerated assets in specialty and a record 20+ Phase III starts in 2026.

Oncology: The New Engine

The centerpiece is the ADC platform. Mo-rez and Ris-rez have moved at unprecedented speed, with 5 and 4 Phase III studies respectively now underway. Hesham Abdullah, global head of oncology R&D, highlighted the confidence: “We've already advanced both ADCs into pivotal programs based on an extensive range of clinical data spanning across ovarian, endometrial, small cell and prostate cancer.” — Hesham Abdullah, Global Head of Oncology R&D · 2026-07-28 The recent Nuvalent acquisition adds precision lung cancer assets, and the Lung Cancer franchise is now a key growth driver. The company is also pushing into GIST with velzatinib and expanding Blenrep into frontline multiple myeloma. The oncology pipeline is arguably the most diversified in GSK's history, a stark contrast to the late stage portfolio of a few years ago.

HIV and Vaccines: Protecting the Base

In HIV, the long-acting story continues, with Cabenuva and Apretude growing 33% and 39% respectively. Charlotte Allerton detailed next-generation candidates: “Our 3 times a year treatment constituting novel formulations of cabotegravir and rilpivirine is compelling.” — Charlotte Allerton, Head of R&D and CSO for ViiV Healthcare · 2026-07-28 The pipeline includes a novel capsid inhibitor (VH499) and a third-generation integrase inhibitor (VH184), extending IP protection into the 2040s. On vaccines, Sanjay Gurunathan presented a bold thesis linking Shingrix to cardiovascular and cognitive benefits, citing a 25% drop in major adverse cardiovascular events and up to 50% risk reduction in dementia symptoms in observational studies.

We've now seen through several observational studies, risk reductions of dementia symptoms up to 50%.

Margin Through the Transition

Financially, CFO Julie Brown emphasized that the dolutegravir loss of exclusivity period (2028-30) will be navigated with margin stability or improvement, thanks to the cost program and mix shift toward specialty. The guidance for 2026 was lifted toward the upper half of the range, with EPS in the lower half due to Nuvalent interest costs. The margin story is now underpinned by a standard of care portfolio that is more resilient than the market fears.

This builds on prior commentary, such as when Luke Miels noted: “we've obviously been very busy. There's been a very aggressive prosecution of opportunities to accelerate the late-stage pipeline.” — Luke Miels, CEO · 2026-04-29 The £40bn 2031 sales target remains a commitment, with Emma Walmsley last year stating: “we are well on track to be delivering this year, 6 years early.” — Emma Walmsley, Chief Executive Officer (CEO) · 2025-10-29 The event was a clear attempt to reset the narrative: GSK is no longer a diversified pharma with a promising pipeline; it is a specialty-focused, pipeline-rich company with a disciplined capital allocation framework. The $10bn+ market cap company (actually £bn) is trading at a discount to peers, and this update could be the catalyst to re-rate.